Regeneron said Monday it will “prioritize the privacy, security and ethical use” of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt 23andMe Holding Co.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.